Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
April 05, 2023 08:30 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress
March 22, 2023 16:01 ET
|
Surrozen, Inc.
Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024...
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
March 20, 2023 16:30 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022...
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 16:41 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:30 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
October 10, 2022 08:00 ET
|
Surrozen, Inc.
SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data shows improved intestinal...
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
October 06, 2022 08:00 ET
|
Surrozen, Inc.
The collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds in developmentSurrozen's novel antibody-based approach targets Fzd4 biology, which has been...
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
September 26, 2022 08:00 ET
|
Surrozen, Inc.
Results highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth into physiological...
Surrozen Reports Second Quarter 2022 Financial Results
August 11, 2022 08:00 ET
|
Surrozen, Inc.
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in Q2 continue to validate Wnt modulation for...
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
June 13, 2022 08:00 ET
|
Surrozen, Inc.
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1First part of two-part Phase 1 trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., June...